Breast Cancer Clinical Trial

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Summary

This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of breast cancer with evidence of a) metastatic or b) locally recurrent/advanced disease.

Exclusion Criteria:

Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

30

Study ID:

NCT01876251

Recruitment Status:

Terminated

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35233, United States
University of Alabama at Birmingham, IDS Pharmacy
Birmingham Alabama, 35249, United States
University of Alabama at Birmingham
Birmingham Alabama, 35249, United States
Stanford Cancer Institute
Stanford California, 94305, United States
Stanford Hospital & Clinics-DRUG SHIPMENT ADDRESS only
Stanford California, 94305, United States
Stanford Hospital & Clinics
Stanford California, 94305, United States
Stanford Women's Cancer Center
Stanford California, 94305, United States
Barbara Ann Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Karmanos Cancer Institute (KCI)
Detroit Michigan, 48201, United States
UNC Cancer Hospital Infusion Pharmacy
Chapel Hill North Carolina, 27514, United States
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill North Carolina, 27599, United States
Jules Bordet Institut
Bruxelles , 1000, Belgium
Grand Hopital de Charleroi
Charleroi , 6000, Belgium
Instituto Europeo di Oncologia
Milano , 20141, Italy
Instituto Catalan de Oncologia de L'Hospitalet de Llobregat(ICO)
Barcelona , 08908, Spain
Hospital Universitario 12 de Octubre
Madrid , 28041, Spain

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

30

Study ID:

NCT01876251

Recruitment Status:

Terminated

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider